In brief
- UTHealth announced a $50 million IMPACT award. A July Psychedelics Today briefing reported a phase 1 launch and supplementary funding, but first dosing, a trial registry and a primary supplementary budget document were not verified here.
- The program is led by UTHealth Houston alongside the University of Texas Medical Branch in Galveston, heading the IMPACT consortium, which brings together a dozen Texas universities and hospitals.
- Texas Tribune reported that private proposals did not meet funding requirements; this does not establish that no company was interested.
Texas announced funding for ibogaine research through IMPACT. A July briefing described a phase 1 launch, but that report is not verification of first dosing or enrollment. The alkaloid comes from the Tabernanthe iboga, with research proposed for addiction, PTSD and brain injury; these are not established efficacy indications or FDA approval.
A state turned trial sponsor
The 2025 Texas initiative allocated $50 million for research. Texas Tribune reported that private partnership proposals did not meet funding requirements, including matching funds and returns to the state. This is neither absence of interest nor proof of each company’s motives. In December 2025 UTHealth announced the award to lead IMPACT with UTMB.
The IMPACT consortium
The contract was awarded to UTHealth Houston, in collaboration with the University of Texas Medical Branch (UTMB) in Galveston, leading an alliance dubbed IMPACT (Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma). The consortium includes, among others, Texas Tech, the University of Texas at Austin, San Antonio, Tyler, and the Rio Grande Valley, Texas A&M, Baylor College of Medicine, and the JPS Health Network in Dallas. According to the July 20 Psychedelics Today policy briefing, the first phase 1 trials have already launched, and the state has also approved supplemental budget reimbursements for trial costs, statements in that briefing not verified here against a first-dose record or primary budget document.
Why it matters
Ibogaine is experiencing a unique moment in the United States. As we reported a few days ago, federal research measures were announced, as described in our report on federal coordination of psychedelic research. The Texas move adds a missing piece: public funding for still-open clinical questions, with specific private-partnership requirements. Nevertheless, it is wise to maintain the caution we always advocate: ibogaine is not a benign substance—cardiac risk requires research and oversight, which do not guarantee zero risk—and precisely for that reason, the framework of a trial with continuous cardiac monitoring is the appropriate place to answer whether its promising observational data in addiction holds up in a controlled trial. More context in our Iboga and Ibogaine Guide.
Sources
- Texas to conduct its own ibogaine clinical trials. The Texas Tribune, March 31, 2026.
- Psychedelic Policy Briefing: Week of July 20th, 2026. Psychedelics Today, July 20, 2026.
- Texas will launch its own clinical trials into ibogaine psychedelic. Texas Standard.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
